163 related articles for article (PubMed ID: 31649050)
1. A Compendium of the Biological Effects of Apolipoprotein A-I
Parolini C
J Pharmacol Exp Ther; 2020 Jan; 372(1):54-62. PubMed ID: 31649050
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides.
Gomaraschi M; Calabresi L; Rossoni G; Iametti S; Franceschini G; Stonik JA; Remaley AT
J Pharmacol Exp Ther; 2008 Feb; 324(2):776-83. PubMed ID: 18042829
[TBL] [Abstract][Full Text] [Related]
3. APOA-1Milano muteins, orally delivered via genetically modified rice, show anti-atherogenic and anti-inflammatory properties in vitro and in Apoe
Romano G; Reggi S; Kutryb-Zajac B; Facoetti A; Chisci E; Pettinato M; Giuffrè MR; Vecchio F; Leoni S; De Giorgi M; Avezza F; Cadamuro M; Crippa L; Leone BE; Lavitrano M; Rivolta I; Barisani D; Smolenski RT; Giovannoni R
Int J Cardiol; 2018 Nov; 271():233-239. PubMed ID: 29907443
[TBL] [Abstract][Full Text] [Related]
4. ApoA-I Milano/phospholipid complexes emerging pharmacological strategies and medications for the prevention of atherosclerotic plaque progression.
Kaul S; Shah PK
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):471-9. PubMed ID: 16503867
[TBL] [Abstract][Full Text] [Related]
5. Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases.
Calabresi L; Sirtori CR; Paoletti R; Franceschini G
Curr Atheroscler Rep; 2006 Mar; 8(2):163-7. PubMed ID: 16510051
[TBL] [Abstract][Full Text] [Related]
6. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice.
Franceschini G; Calabresi L; Chiesa G; Parolini C; Sirtori CR; Canavesi M; Bernini F
Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1257-62. PubMed ID: 10323777
[TBL] [Abstract][Full Text] [Related]
7. Infusions of Large Synthetic HDL Containing Trimeric apoA-I Stabilize Atherosclerotic Plaques in Hypercholesterolemic Rabbits.
Parolini C; Adorni MP; Busnelli M; Manzini S; Cipollari E; Favari E; Lorenzon P; Ganzetti GS; Fingerle J; Bernini F; Chiesa G
Can J Cardiol; 2019 Oct; 35(10):1400-1408. PubMed ID: 31495683
[TBL] [Abstract][Full Text] [Related]
8. High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients.
Kempen HJ; Asztalos BF; Moerland M; Jeyarajah E; Otvos J; Kallend DG; Bellibas SE; Wijngaard PL
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):736-42. PubMed ID: 26916733
[TBL] [Abstract][Full Text] [Related]
9. CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.
Gille A; D'Andrea D; Tortorici MA; Hartel G; Wright SD
Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):953-963. PubMed ID: 29437574
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.
Sherman CB; Peterson SJ; Frishman WH
Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699
[TBL] [Abstract][Full Text] [Related]
11. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
Curr Opin Lipidol; 2004 Dec; 15(6):645-9. PubMed ID: 15529023
[TBL] [Abstract][Full Text] [Related]
12. ApoA-IMilano phospholipid complex (ETC-216) infusion in human volunteers. Insights into the phenotypic characteristics of ApoA-IMilano carriers.
Bisgaier CL; Ackermann R; Rea T; Rodrigueza WV; Hartman D
Pharmacol Res; 2016 Sep; 111():86-99. PubMed ID: 27155060
[TBL] [Abstract][Full Text] [Related]
13. Microarray analysis identifies human apoA-I
Ganzetti GS; Parolini C
Exp Cell Res; 2023 Dec; 433(1):113826. PubMed ID: 37858836
[TBL] [Abstract][Full Text] [Related]
14. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides.
Anantharamaiah GM; Mishra VK; Garber DW; Datta G; Handattu SP; Palgunachari MN; Chaddha M; Navab M; Reddy ST; Segrest JP; Fogelman AM
J Lipid Res; 2007 Sep; 48(9):1915-23. PubMed ID: 17570869
[TBL] [Abstract][Full Text] [Related]
15. Systematic evaluation of the effect of different apolipoprotein A-I mimetic peptides on the performance of synthetic high-density lipoproteins in vitro and in vivo.
Yuan W; Ernst K; Kuai R; Morin EE; Yu M; Sviridov DO; Tang J; Mei L; Li D; Ackermann R; Remaley AT; Schwendeman A
Nanomedicine; 2023 Feb; 48():102646. PubMed ID: 36549559
[TBL] [Abstract][Full Text] [Related]
16. Evidence that apolipoprotein A-IMilano has reduced capacity, compared with wild-type apolipoprotein A-I, to recruit membrane cholesterol.
Bielicki JK; McCall MR; Stoltzfus LJ; Ravandi A; Kuksis A; Rubin EM; Forte TM
Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1637-43. PubMed ID: 9327756
[TBL] [Abstract][Full Text] [Related]
17. Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer.
Calabresi L; Canavesi M; Bernini F; Franceschini G
Biochemistry; 1999 Dec; 38(49):16307-14. PubMed ID: 10587455
[TBL] [Abstract][Full Text] [Related]
18. HDL therapy for the treatment of cardiovascular diseases.
Parolini C; Marchesi M; Chiesa G
Curr Vasc Pharmacol; 2009 Oct; 7(4):550-6. PubMed ID: 19485919
[TBL] [Abstract][Full Text] [Related]
19. Comparative antiatherogenic effects of intravenous AAV8- and AAV2-mediated ApoA-IMilano gene transfer in hypercholesterolemic mice.
Tian F; Wang L; Arias A; Yang M; Sharifi BG; Shah PK
J Cardiovasc Pharmacol Ther; 2015 Jan; 20(1):66-75. PubMed ID: 24742767
[TBL] [Abstract][Full Text] [Related]
20. Synthetic high density lipoproteins for the treatment of myocardial ischemia/reperfusion injury.
Calabresi L; Gomaraschi M; Rossoni G; Franceschini G
Pharmacol Ther; 2006 Sep; 111(3):836-54. PubMed ID: 16960983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
